370 related articles for article (PubMed ID: 22015718)
21. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
22. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
23. Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice.
Kladney RD; Cardiff RD; Kwiatkowski DJ; Chiang GG; Weber JD; Arbeit JM; Lu ZH
Cancer Res; 2010 Nov; 70(21):8937-47. PubMed ID: 20940396
[TBL] [Abstract][Full Text] [Related]
24. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
[TBL] [Abstract][Full Text] [Related]
25. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Rodrik-Outmezguine VS; Chandarlapaty S; Pagano NC; Poulikakos PI; Scaltriti M; Moskatel E; Baselga J; Guichard S; Rosen N
Cancer Discov; 2011 Aug; 1(3):248-59. PubMed ID: 22140653
[TBL] [Abstract][Full Text] [Related]
26. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
[TBL] [Abstract][Full Text] [Related]
27. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
28. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.
Willems L; Tamburini J; Chapuis N; Lacombe C; Mayeux P; Bouscary D
Curr Oncol Rep; 2012 Apr; 14(2):129-38. PubMed ID: 22350330
[TBL] [Abstract][Full Text] [Related]
29. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.
Yi J; Zhu J; Wu J; Thompson CB; Jiang X
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31189-31197. PubMed ID: 33229547
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
Ellis L; Ku SY; Ramakrishnan S; Lasorsa E; Azabdaftari G; Godoy A; Pili R
Oncotarget; 2013 Dec; 4(12):2225-36. PubMed ID: 24163230
[TBL] [Abstract][Full Text] [Related]
32. Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release.
Kuehn HS; Jung MY; Beaven MA; Metcalfe DD; Gilfillan AM
J Biol Chem; 2011 Jan; 286(1):391-402. PubMed ID: 20980255
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Fan QW; Weiss WA
Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
[TBL] [Abstract][Full Text] [Related]
34. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
[TBL] [Abstract][Full Text] [Related]
35. PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells.
Matsumoto CS; Almeida LO; Guimarães DM; Martins MD; Papagerakis P; Papagerakis S; Leopoldino AM; Castilho RM; Squarize CH
Oncotarget; 2016 Jul; 7(27):42393-42407. PubMed ID: 27285754
[TBL] [Abstract][Full Text] [Related]
36. Growing knowledge of the mTOR signaling network.
Huang K; Fingar DC
Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
[TBL] [Abstract][Full Text] [Related]
37. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B; Warne PH; Downward J
Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
[TBL] [Abstract][Full Text] [Related]
38. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
39. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.
Liu Q; Kirubakaran S; Hur W; Niepel M; Westover K; Thoreen CC; Wang J; Ni J; Patricelli MP; Vogel K; Riddle S; Waller DL; Traynor R; Sanda T; Zhao Z; Kang SA; Zhao J; Look AT; Sorger PK; Sabatini DM; Gray NS
J Biol Chem; 2012 Mar; 287(13):9742-9752. PubMed ID: 22223645
[TBL] [Abstract][Full Text] [Related]
40. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
